

Message

From: Tyler, Amber [amber.tyler@mallinckrodt.com]
Sent: 9/30/2014 8:16:01 PM
To: wright, lawrence
CC: garber, anna; gatley, rob; Decker, John F [john.decker@mallinckrodt.com]; Purcell, Tina M [tina.purcell@mallinckrodt.com]
Subject: Upcoming Abstracts ASPAN & AMCP

Larry,

As per our conversation the following abstracts will be submitted to ASPAN by October 10, 2014:

1. Abuse quotient analysis of HAL data (MNK-155-original submission)
2. Study 232 OLE (MNK-155- Original)
3. Study 232 speed of onset (MNK-155 - Original)
4. Study 182 speed of onset (XXR - Original)

The following abstracts will be submitted to AMCP by October 13, 2014

1. Study 232 speed of onset (MNK-155 i½ encore)
2. Study 375 HAL PK-PD (MNK-155 i½ encore)
3. Integrated safety (MNK-155 i½ original)
4. Study 182 speed of onset (XXR i½ encore)
5. Study 244 HAL PK-PD (XXR i½ encore)
6. Integrated safety (XXR i½original)

Thank you for your time,

Amber

Amber Tyler, Ph.D. | Medical Writer, Scientific Communications | Medical Affairs

Mallinckrodt Pharmaceuticals
675 McDonnell Blvd. | Hazelwood, MO 63042 | USA

Office: 314-654-8412
amber.tyler@mallinckrodt.com

..